Harmaline
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Harmaline is a naturally-occurring psychoactive alkaloid of the β-carboline class. It is the primary MAO-A inhibiting alkaloid in Syrian rue seeds and ayahuasca vine. It blocks the breakdown of serotonin, norepinephrine, and dopamine in the brain, producing sedation and emotional enhancement.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Goebel first isolated harmaline from Peganum harmala seeds around 1837–1841;[2] Manske confirmed the structure by total synthesis in 1927. It became the standard laboratory model for essential tremor research,[3] then gained recognition as the compound that makes ayahuasca orally active.[4] Today it is encountered mainly in Syrian rue seeds and ayahuasca preparations used in ceremonial contexts worldwide.
Subjective effects include sedation, nausea, emotional intensification, bodily heaviness, and motor impairment.[5] The experience is defined by somatic weight and introspective gravity — less euphoric and more physically demanding than classical psychedelics. Tremor, difficulty with coordination, and vomiting are characteristic at higher doses.
Harmaline does not produce physical dependence, and no lethal dose has been established for the pure compound. The primary danger is combining it with antidepressants or other serotonin-raising drugs, which can trigger serotonin syndrome — a life-threatening overheating and seizure response.[6] No controlled human studies of isolated harmaline exist; all evidence comes from ayahuasca research, making it one of the least well-characterized psychoactive alkaloids in human pharmacology.
History[edit]
Discovery
Goebel isolated harmaline from Peganum harmala seeds around 1837–1841.[2] J. Fritzsche independently investigated the same alkaloids in 1847. Richard Manske's total synthesis in 1927 confirmed the correct structure — a β-carboline scaffold with partial ring saturation.[2]
Scientific significance
Harmaline became the standard laboratory model for essential tremor research: injecting it into experimental animals produces a reliable, reversible postural tremor.[3] In 1984, McKenna et al. published the landmark characterization of β-carboline alkaloids in ayahuasca, establishing how harmaline and harmine enable oral DMT activity.[4] That paper defined the pharmacological understanding of ayahuasca synergy.
Modern research
Contemporary research has expanded into neuroplasticity,[7] neuroprotection against oxidative damage,[8] anti-inflammatory activity,[9] and ion channel pharmacology.[10] No clinical trials of isolated harmaline have been initiated. All clinical investigation proceeds within ayahuasca preparations.
Harmaline-containing plants were used long before Western chemistry arrived. Residues of P. harmala in a Ptolemaic Egyptian ritual vessel dated to the 2nd century BCE are the earliest confirmed archaeological evidence.[11] Across North Africa, the Middle East, and Central Asia, the seeds served as incense, fumigant, abortifacient, and folk antidepressant in multiple cultural traditions.[12]
Chemistry[edit]
Structural class
Harmaline belongs to the β-carboline family — a group of indole alkaloids built biosynthetically from tryptophan.[13] It is a 3,4-dihydro-β-carboline: the pyridine ring is partially saturated, distinguishing it from its fully aromatic relative harmine. This partial saturation gives harmaline higher MAO-A selectivity and better brain penetration than harmine, but lower metabolic stability.[14]
Molecular properties
Its molecular formula is C₁₃H₁₄N₂O (molecular weight 214.26 g/mol).[15] Harmaline is a crystalline solid with a melting point of 229–232°C and fluoresces blue-green under ultraviolet light.[16] It can also form endogenously in mammals through a reaction between tryptophan-derived compounds and aldehydes, though the physiological significance of this is unknown.[13]
Pharmacology[edit]
Mechanism of action
MAO-A inhibition
Harmaline's primary action is blocking MAO-A (MAO-A), the enzyme that breaks down serotonin, norepinephrine, and dopamine.[1] The block is potent and reversible — enzyme activity recovers once harmaline clears. This raises neurotransmitter levels throughout the brain and prevents the gut from destroying oral DMT, which is how ayahuasca works.[4]
Secondary mechanisms
Beyond MAO-A, harmaline amplifies calcium signaling in a cluster of brainstem nerve cells called the inferior olive, causing synchronized electrical oscillations that produce the characteristic tremor.[17] This tremorigenic effect made harmaline the standard laboratory model for essential tremor research for over five decades.
Pharmacokinetics
Harmaline is absorbed through the intestinal lining and, unlike harmine, is not actively expelled from intestinal cells — giving it higher oral bioavailability and slower clearance.[14] The liver converts it primarily into harmalol via a metabolic enzyme called CYP2D6.[13] People who carry slow variants of this enzyme — about 5–10% of Europeans — clear harmaline more slowly and experience stronger, longer effects.
Neuroscience[edit]
Where it acts
Harmaline's most thoroughly understood action targets the olivocerebellar circuit — the connection between the brainstem's inferior olive and the cerebellum. It amplifies calcium signaling in inferior olive nerve cells, generating synchronized oscillations that produce the characteristic postural tremor.[17] This mechanism has served as the standard research model for essential tremor for over five decades.[3]
Beyond the cerebellum, MAO-A inhibition raises monoamine levels across widespread brain networks. Neuroimaging after ayahuasca shows increased blood flow in frontal and limbic regions — areas linked to introspection, emotional processing, and autobiographical memory.[18]
Why it matters
Harmaline promotes new neuron growth in laboratory studies — neural stem cells showed increased proliferation and maturation after exposure.[7] This is a candidate mechanism for the antidepressant effects observed in ayahuasca clinical trials.[19] Harmaline also protects brain tissue against oxidative damage relevant to Parkinson's disease pathology.[8][20]
- Does harmaline reach psychoactively relevant concentrations in the human brain when taken orally alone, or does its main role in ayahuasca lie in the gut — preventing DMT from being destroyed before absorption?
- Does the new neuron growth seen in laboratory cell cultures translate to structural brain changes at doses humans actually encounter?
- People with slow CYP2D6 enzyme activity are predicted to accumulate significantly more harmaline — but this has not been confirmed in controlled studies.
Subjective Effects[edit]
Harmaline's contribution to ayahuasca — and its character in isolation — is defined by physical weight: a sedating, somatically heavy state with near-universal nausea, emotional intensification, and a gravitational pull toward inward attention. The emotional tone is serious rather than euphoric, and motor coordination deteriorates with dose.
Compared to classical psychedelics like psilocybin or LSD, harmaline occupies different territory. Direct visual distortion is minimal and euphoric lift is largely absent. The experience is better understood as a potent monoamine shift with heavy somatic character — closer in feel to a clinical antidepressant than to a tryptamine or lysergamide psychedelic.
Effect Grid
Clear sedation develops alongside prominent emotional enhancement and an introspective quality. Thoughts may turn inward with increased emotional depth and personal significance. Mood elevation is present but the character is contemplative rather than euphoric — a gravity of feeling rather than lightness.
Nausea becomes a defining feature at this tier, with gastrointestinal disturbance reliably present. Bodily heaviness is pronounced, and motor control impairment begins to manifest. Dizziness is possible. Trembling may emerge at the upper end of this range.
Functional impairment is significant. The experience demands a committed setting — 4–5 hours of reduced capacity. Avoid all machinery and driving.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color alteration · Geometry · Light sensitivity · Spatial disorientation · Vestibular distortion · Color enhancement · Depth perception distortion · Proprioceptive distortion · Tracers · Visual breathing · Visual drifting · Visual haze / noise · Environmental patterning · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations
Vestibular distortion · Color enhancement · Depth perception distortion · Proprioceptive distortion · Tracers · Visual breathing · Visual drifting · Visual haze / noise · Environmental patterning · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations
Involuntary body movements · Nystagmus (eye wobbles) · Pupil dilation · Sedation · Vomiting · Bodily heaviness · Physical fatigue · Stimulation · Vibrations / buzzing · Heart rate perception changes · Appetite suppression · Body high · Body schema distortion · Breathing alteration · Excessive sweating · Headache · Insomnia · Muscle tension · Restlessness · Spontaneous body sensations · Vasoconstriction · Wakefulness · Diarrhea · Tingling / electric sensations
Sedation · Vomiting · Bodily heaviness · Physical fatigue · Stimulation · Vibrations / buzzing · Heart rate perception changes · Appetite suppression · Body high · Body schema distortion · Breathing alteration · Excessive sweating · Headache · Insomnia · Muscle tension · Restlessness · Spontaneous body sensations · Wakefulness · Diarrhea · Tingling / electric sensations
Confusion · Information processing suppression · Openness enhancement · Cognitive dysphoria · Cognitive euphoria · Conceptual thinking · Focus suppression · Memory fragmentation · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Thought disorganization · Creativity enhancement · Thought loops
Cognitive euphoria · Conceptual thinking · Focus suppression · Memory fragmentation · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Thought disorganization · Creativity enhancement · Thought loops
Dysphoria · Empathy enhancement · Euphoria · Simultaneous emotions · Irritability
Irritability
Sociability suppression · Disinhibition · Boundary dissolution · Identity alteration
Timeline
Initial gastrointestinal awareness develops — mild gastric warmth or faint nausea. Subtle mood shift may be perceptible as MAO-A inhibition begins.
Sedation builds progressively. Nausea intensifies and becomes a prominent feature. Emotional shifts begin — introspective quality emerges alongside bodily heaviness.
Maximum sedation and emotional intensification. Nausea or vomiting may occur at sufficient doses. Strongest introspective and mood effects.
Gradual decrease in sedation and nausea. Emotional effects taper but introspective quality may persist. Motor coordination slowly returns.
Residual mood effects and possible fatigue. Subtle emotional warmth or contemplative quality may linger.
⚠ Avoid driving or operating machinery for at least 6 hours after ingestion due to potential residual sedation and motor impairment.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- harmine · tetrahydroharmine · moclobemide
Toxicity
Acute toxicity
No lethal dose has been established for pure harmaline in any species. A plant extract containing harmaline and harmine showed no toxicity at 3 g/kg over 14 days in rats,[21] but this cannot be attributed to harmaline alone. safety citation needed
Neurotoxicity
At very high experimental doses injected into rodents (20 mg/kg), harmaline produces cerebellar damage including nerve cell death.[22] These doses far exceed any human ceremonial or recreational exposure. inferred
Cardiovascular effects
In controlled ayahuasca studies, cardiovascular effects are modest: blood pressure rises slightly at high doses, with minimal heart rate changes.[5] Harmaline's blood vessel-relaxing properties may moderate this response.[23]
Poisoning reports
Documented poisoning cases from concentrated P. harmala seed preparations include sensory disturbance, hallucinations, slow heart rate, low blood pressure, agitation, tremor, vomiting, and loss of coordination.citation needed These cases involve multiple co-ingested alkaloids and cannot be attributed to harmaline alone. No isolated harmaline overdose cases exist.
Psychological risks
No controlled data on psychological adverse events from pure harmaline exist. In the ayahuasca context, acute anxiety and distress can occur at higher doses, particularly in people with pre-existing psychiatric vulnerability.[24] Low doses appear anxiolytic; higher doses may become anxiety-producing.[25]
Tolerance & Dependence
Tolerance to harmaline's tremor-producing effect develops with repeated use.[17] No physical dependence, withdrawal, or compulsive use pattern has been documented. Long-term ritualistic ayahuasca use consistently shows low abuse potential,[24] and the strong nausea functions as a natural deterrent to dose escalation.[26]
Drug Interactions
As a potent MAO-A inhibitor, harmaline creates serotonin syndrome risk when combined with any drug that raises serotonin. Serotonin syndrome is a potentially life-threatening response involving high fever, muscle rigidity, and seizures.[6] No case has been specifically attributed to isolated harmaline — the warning is a class-level inference from its mechanism. safety citation needed
Serotonergic combinations: SSRIs, SNRIs, tricyclic antidepressants, MAOIs, triptans, tramadol, meperidine, dextromethorphan, lithium, buspirone, and St. John's Wort all add to serotonin excess. Meperidine carries the highest historical fatality risk among opioid-MAOI combinations.[6]
Tyramine reaction: MAO-A inhibition prevents the body from breaking down tyramine from aged cheeses, cured meats, and fermented foods. Accumulated tyramine triggers dangerous blood pressure spikes. Harmaline's reversible mechanism reduces — but does not eliminate — this risk compared to irreversible MAOIs.
CYP2D6 inhibitors: Drugs that slow CYP2D6 — including fluoxetine, paroxetine, bupropion, and quinidine — significantly increase harmaline blood levels and prolong its effects.[13][6]
Tryptamine potentiation: Harmaline dramatically amplifies the oral potency and intensity of DMT and likely other orally administered tryptamines by preventing their gut breakdown.[4][5]
Contraindications
Absolute:
- Concurrent SSRI, SNRI, or MAOI therapy — serotonin syndrome risk. Washout periods appropriate to the medication's half-life are required (typically 2 weeks; 5 weeks for fluoxetine). safety citation needed
- Concurrent meperidine, tramadol, or dextromethorphan — serotonin syndrome and respiratory depression risk.[6]
Relative:
- CYP2D6 poor metabolizer status — substantially elevated harmaline exposure expected.[13]
- Heart disease — insufficient safety data in cardiovascular-compromised populations.[5]
- Liver impairment — impaired metabolism may increase exposure.
- Tyramine-rich diet — blood pressure crisis risk, reduced but not eliminated by reversibility.
- Seizure disorders — monoamine oxidase inhibition may lower seizure threshold. inferred
- Pregnancy — P. harmala has traditional use as an abortifacient;[12] no reproductive safety data exist.
- Psychiatric vulnerability — individuals with personal or family history of psychotic disorders should exercise caution.[24]
Harm Reduction[edit]
Forms & Identification
Harmaline is most often encountered in Peganum harmala seeds, Banisteriopsis caapi vine preparations, or ayahuasca brews. Isolated harmaline powder is rare outside research settings. The central challenge is variability: seed potency differs by origin, batch, and storage, and ayahuasca alkaloid content can vary by an order of magnitude between brews.
Two batches may look identical and produce radically different effects. Reagent testing is less informative for plant materials than for synthetic compounds. Starting conservatively is the most reliable risk reduction strategy.
Guidelines
- Start with a low dose and wait at least 90 minutes before considering redosing — onset is gradual and effects build slowly.
- Fast for 4–6 hours before ingestion to reduce nausea, which is dose-dependent and often intense.
- Avoid all tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce) for at least 12 hours before and after ingestion.
- Have a bucket or basin nearby. Vomiting is common, especially with seed or ayahuasca preparations.
- Remain seated or lying down at higher doses — motor impairment and tremor can make movement unsafe.
- Do not drive or operate machinery for at least 8 hours after ingestion.
Set & Setting
Harmaline's sedating, physically heavy, and emotionally intensifying character makes physical comfort and psychological safety especially important. A calm, familiar environment with easy access to a bathroom is essential — nausea is near-universal with harmaline-containing preparations.
The introspective and emotionally weighted quality of the experience favors a setting free of social pressure. A trusted sitter is strongly recommended at higher doses, where motor impairment and disorientation increase. The sitter should expect nausea and possible tremor — neither necessarily indicates a medical emergency.
Aftercare & integration. The somatic intensity of harmaline experiences — nausea, tremor, bodily heaviness — can leave the body depleted. Hydration and light, easily digestible food in the hours after support physical recovery. Rest is advisable; the sedating quality often makes sleep accessible.
The emotionally weighted, introspective character frequently surfaces difficult material. Journaling within 24 hours helps preserve insights and process challenging content. If the experience produced significant distress, support from a therapist familiar with psychoactive experiences is appropriate.
Recovery & Support
Harmaline does not produce physical dependence, and compulsive use patterns have not been documented. The strong emetic properties of harmaline-containing preparations act as a natural deterrent to escalation. If use becomes a pattern of avoidance rather than intentional practice, professional support is warranted. Integration circles and harm reduction organizations can provide non-judgmental guidance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most harmaline experiences involve nausea and physical discomfort that resolve without intervention. Seek immediate medical help if any of the following occur: severe uncontrollable vomiting lasting more than an hour, rigid or jerking muscles with high fever (possible serotonin syndrome), seizures, loss of consciousness, chest pain, or extreme agitation with confusion.
Immediate steps:
- Call emergency services if any of the above signs are present.
- Place the person on their side (recovery position) if vomiting or unresponsive.
- Do not restrain unless in immediate physical danger.
- Keep cool if body temperature appears elevated.
- Do not induce vomiting.
What to tell the dispatcher: Name the substance (harmaline, Syrian rue seeds, or ayahuasca), approximate amount and time of ingestion, current symptoms, and any other substances taken — including prescription medications. Good Samaritan laws in many jurisdictions protect people who call for help.
Legal Status[edit]
Harmaline is not scheduled under any United Nations drug convention,[27] but several individual nations have enacted specific controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Nations | Not scheduled | Not on INCB Yellow, Green, or Red Lists[27] |
| United States | Uncontrolled (federal) | Not listed in Controlled Substances Act schedules. USDA confiscates international P. harmala plant shipments as an invasive species, but the alkaloid itself is not scheduled. Federal Analogue Act applicability unclear for human consumption contexts[28] |
| Canada | Schedule III (CDSA) | Controlled under the Controlled Drugs and Substances Act[28] |
| Australia | Schedule 9 (Prohibited) | Prohibited under Therapeutic Goods Act; import/export prohibited under Customs Act 1901 Schedule 4. Queensland classifies as Schedule 2 dangerous drug. Exception for preparations containing ≤2 mg per dosage unit[28] |
| France | Controlled | Listed as plante vénéneuse since 2005 under French Public Health Code; sale and distribution prohibited[27] |
| United Kingdom | Not specifically scheduled | Not listed in Misuse of Drugs Act schedules; legal to possess and supply as of available data[28] citation needed |
| Germany | Not specifically scheduled | Not listed under Betäubungsmittelgesetz (BtMG); status under Neue-psychoaktive-Stoffe-Gesetz (NpSG) unclear citation needed |
| Netherlands | Not scheduled | Not listed in Opium Act citation needed |
Legal status data is sourced from secondary references rather than primary legislative texts and should be verified against current legislation before reliance.
Analog and prodrug considerations
In jurisdictions where harmaline is not specifically scheduled, its presence in widely available plant material creates a regulatory gray zone. The US Federal Analogue Act may apply if sold for human consumption, though no federal prosecution on this basis has been reported. citation needed
Legal status data is sourced from secondary references. Laws change frequently. Verify current legislation in any jurisdiction before relying on this information.
references
- [1] ^abHerraiz T, Brandt SD (2014) 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO) — Drug Testing and Analysis doi:10.1002/dta.1530
- [2]
- [3] ^abcHandforth A (2012) Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor — Tremor and other hyperkinetic movements doi:10.7916/d8td9w2p
- [4]
- [5] ^abcdRiba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ (2003) Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics — Journal of Pharmacology and Experimental Therapeutics PMID:12660312
- [6]